New study shows triple inhaler helps COPD patients breathe easier
NCT ID NCT05535972
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how well a single inhaler containing three medicines (Trelegy Ellipta) works for people with chronic obstructive pulmonary disease (COPD) in real-world settings. Over 12 weeks, 463 adults aged 40 and older with ongoing COPD symptoms used the inhaler. Researchers measured changes in health status, shortness of breath, and lung function to see if the treatment improved daily life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY DISEASE, CHRONIC OBSTRUCTIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Dongguan, 523326, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Virtual Nurse-Social worker team aims to ease symptoms for veterans with heart failure and COPD
- Double-Duty inhaler aims to ease breathing in COPD
- Could AI help pharmacists give better advice?
- New COPD drug tested across chinese, japanese, and european volunteers
- New digital tool aims to simplify care for seniors with multiple conditions
- Nose sensor could replace needle sticks for CO2 monitoring